Else Nutrition cheers U.S. House legislation

Executive Summary

• Else Nutrition Holdings Inc. publicly supports the U.S. House of Representatives Committee on Appropriations for passing the FY2026 Appropriations Bill, which includes specific language supporting the expansion of plant-based, non-soy, and non-dairy infant formulas.
• The legislation directs the FDA to streamline approval pathways for small domestic manufacturers and establish formal regulatory guidance for these alternative formulas, aiming to address allergies, intolerances, and ethical dietary preferences.
• The company views this as a pivotal moment for market access, noting that while the report language is non-binding, it signals strong Congressional momentum and may influence FDA priorities and resource allocation.

Key Details

• Legislative Action: The U.S. House of Representatives Committee on Appropriations passed the FY2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Bill.
• Regulatory Directives: The accompanying report directs the FDA to:
  • Streamline approval pathways for small domestic manufacturers.
  • Provide formal regulatory guidance around non-dairy, non-soy plant-based formulas.
• Target Demographics: The legislation aims to support infants with allergies, intolerances, or sensitivities to traditional ingredients, as well as families seeking alternatives for health, lifestyle, or ethical reasons.
• Operational Context: The bill highlights the "Operation Stork Speed" initiative, elevating plant-based, non-dairy, non-soy formulations as a key component to fast-track innovation in the infant formula space.
• Company Position: CEO Hamutal Yitzhak describes this as a "turning point" and a "powerful indication of Congressional momentum," emphasizing that the path to broader U.S. market access is becoming more defined.
• Next Steps: The legislation still requires passage by the full House before becoming law, though the committee report often shapes agency behavior.

Notable Quotes

• "This marks a turning point for American families and for Else Nutrition... This legislative milestone signals that change is coming -- toward a more inclusive and diversified infant formula landscape." — Hamutal Yitzhak, CEO and Co-founder
• "This is the clearest signal yet that U.S. policymakers are aligned with what we at Else have long championed -- that every child deserves access to safe, effective and nutritionally complete formula options." — Hamutal Yitzhak, CEO and Co-founder